Panbela Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 2011
Net Income	-27.26	-25.26	-34.93	-10.14	-4.77	-6.2	Upgrade
Depreciation & Amortization	0	0	0	0	0.11	2.07	Upgrade
Share-Based Compensation	0.75	0.82	1.09	1.29	1.21	1.09	Upgrade
Other Operating Activities	1.62	-0.81	18.57	2.14	-0.41	0.3	Upgrade
Operating Cash Flow	-24.89	-25.25	-15.28	-6.7	-3.85	-2.74	Upgrade
Capital Expenditures	0	0	-0.66	0	0	0	Upgrade
Acquisitions	0	0	0	0	0	0	Upgrade
Other Investing Activities	0.4	0.4	-	-0.54	-	-	Upgrade
Investing Cash Flow	0.4	0.4	-0.66	-0.54	0	0	Upgrade
Common Stock Issued	15.78	23.05	5.35	9.05	11.08	3.16	Upgrade
Share Repurchases	0	-0.01	0	0	0	0	Upgrade
Other Financing Activities	3.75	3.08	0.01	1.04	-0.64	0.62	Upgrade
Financing Cash Flow	19.52	26.14	5.35	10.1	10.44	3.78	Upgrade
Net Cash Flow	-4.97	1.29	-10.58	2.85	6.57	1.04	Upgrade
Free Cash Flow	-24.89	-25.25	-15.94	-6.7	-3.85	-2.74	Upgrade
Free Cash Flow Per Share	-7.96	-232300.74	-18588.99	-13741.18	-11961.39	-11532.00	Upgrade

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.